Abstract
Glioblastoma
is
the
most
common
and
highly
invasive
glial
tumor,
significantly
reducing
patient
survival.
Current
therapeutic
approaches
have
limited
success
rates.
Plant-derived
nanovesicles
are
a
rapidly
developing
area,
recognized
for
their
exceptional
biofunctional
properties,
emerging
as
promising
approach
in
cancer
treatment.
The
present
study
focuses
on
isolation
of
from
Viburnum
opulus
fruits
using
cost-effective
method
that
includes
polymer-based
exosome
precipitation
buffer
size
exclusion
chromatography,
followed
by
characterization.
Morphological
analysis
via
Field
Emission
Scanning
Electron
Microscopy
Transmission
revealed
ranging
oval
to
elliptical
shapes,
with
average
diameters
54.23
nm
41.21
nm,
respectively.
Dynamic
light
scattering
determined
45.36
indicating
presence
nanovesicles,
zeta
potential
was
−
2.87
mV.
Biochemical
characterization
showed
total
protein
phenolic
concentrations
1534
±
97.78
µg/ml
4.270
0.66
mg
gallic
acid
equivalents/L,
respectively,
antioxidant
status
values
3.83
0.37
mmol
Trolox
equivalents/L.
Based
IC50
values,
these
were
7.5
times
more
toxic
U87MG
human
glioblastoma
cells
compared
healthy
dermal
fibroblasts.
Analyses
including
clonogenic
cell
survival,
wound
healing,
apoptosis,
status,
oxidant
continued
only
cells,
fibroblasts
low
response
nanovesicle
Qualitative
quantitative
assessments
demonstrated
-derived
effectively
inhibited
proliferation
migration.
Due
non-toxic,
anticancer,
hold
significant
management.
Graphical
abstract
Medical Sciences,
Год журнала:
2023,
Номер
12(1), С. 1 - 1
Опубликована: Дек. 23, 2023
One
of
the
most
prevalent
primary
malignant
brain
tumors
is
glioblastoma
(GB).
About
6
incidents
per
100,000
people
are
reported
annually.
Most
frequently,
these
linked
to
a
poor
prognosis
and
quality
life.
There
has
been
little
advancement
in
treatment
GB.
In
recent
years,
some
innovative
medicines
have
tested
for
newly
diagnosed
cases
GB
recurrent
Surgery,
radiotherapy,
alkylating
chemotherapy
all
common
treatments
A
few
potential
alternatives
include
immunotherapy,
tumor-treating
fields
(TTFs),
medications
that
target
specific
cellular
receptors.
To
provide
new
multimodal
therapies
focus
on
molecular
pathways
implicated
tumor
initiation
progression
GB,
novel
medications,
delivery
technologies,
immunotherapy
approaches
being
researched.
Of
these,
oncolytic
viruses
(OVs)
among
recent.
Coupling
OVs
with
certain
modern
may
significant
benefits
patients.
Here,
we
discuss
several
how
they
work
conjunction
other
therapies,
as
well
virotherapy
The
study
was
based
PRISMA
guidelines.
Systematic
retrieval
information
performed
PubMed.
total
307
articles
were
found
search
viral
glioblastoma.
Out
83
meta-analyses,
randomized
controlled
trials,
reviews,
systematic
reviews.
42
from
years
2018
2023.
Appropriate
studies
isolated,
important
each
them
understood
entered
into
database
which
used
this
article.
still
Significant
promise
opportunity
exist
boosting
immune
response.
Making
requires
careful
consideration
evaluation
number
its
application
factors.
Journal of Translational Medicine,
Год журнала:
2024,
Номер
22(1)
Опубликована: Фев. 2, 2024
Abstract
Glioblastoma
multiforme
(GBM)
is
the
most
common
malignant
primary
brain
cancer
affecting
adult
population.
Median
overall
survival
for
GBM
patients
poor
(15
months),
primarily
due
to
high
rates
of
tumour
recurrence
and
paucity
treatment
options.
Oncolytic
virotherapy
a
promising
alternative
patients,
where
engineered
viruses
selectively
infect
eradicate
cells
by
inducing
cell
lysis
eliciting
robust
anti-tumour
immune
response.
In
this
study,
we
evaluated
oncolytic
potency
live-attenuated
vaccine
strains
Zika
virus
(ZIKV-LAV)
against
human
in
vitro.
Our
findings
revealed
that
Axl
integrin
α
v
β
5
function
as
cellular
receptors
mediating
ZIKV-LAV
infection
cells.
productively
infected
lysed
but
not
endothelia
terminally
differentiated
neurons.
Upon
infection,
mediated
death
via
apoptosis
pyroptosis.
This
first
in-depth
molecular
dissection
how
ZIKV
infects
induces
Journal for ImmunoTherapy of Cancer,
Год журнала:
2024,
Номер
12(12), С. e009175 - e009175
Опубликована: Дек. 1, 2024
Glioma
evolution
is
governed
by
a
multitude
of
dynamic
interactions
between
tumor
cells
and
heterogenous
neighboring,
non-cancerous
cells.
This
complex
ecosystem,
termed
the
microenvironment
(TME),
includes
diverse
immune
cell
types
that
have
gained
increasing
attention
for
their
critical
paradoxical
roles
in
control
tumorigenesis.
Recent
work
has
revealed
cellular
composition
functional
state
TME
can
evolve
extensively
depending
on
stage
intrinsic
features
surrounding
glioma
Concurrently,
adaptations
to
phenotype,
including
activation
various
states,
occur
context
these
alterations.
In
this
review,
we
summarize
important
play
key
during
each
progression,
from
initiation
escape,
invasion
recurrence.
Understanding
interplay
development
effective
immunotherapies
treatment.
Molecular Pharmaceutics,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 2, 2025
Glioblastoma
multiforme
(GBM)
is
considered
to
be
one
of
the
most
devastating
brain
tumors
with
a
shorter
life
expectancy.
Several
factors
contribute
dismal
prognosis
GBM
patients
including
complicated
nature
GBM,
ability
tumor
cells
resist
treatment,
and
difficulty
delivering
drugs
because
barriers
like
blood-brain
barrier
(BBB)
blood-tumor
(BTB).
The
unique
challenges
posed
by
BBB
in
therapeutic
agents
have
led
development
innovative
nanotechnology-based
approaches.
By
exploiting
olfactory/trigeminal
pathway,
nanosystems
offer
promising
strategy
for
targeted
drug
delivery
brain,
glioblastoma
particular.
This
review
contemplates
varied
nanocarriers,
polymeric
nanoparticles,
lipid-based
nanosystems,
situ
gel
formulations,
peptide,
stem
cell-based
nanoformulations,
signifying
their
utility
targeting
minimal
systemic
side
effects.
Emerging
trends
gene
therapy
immunotherapy
context
treatment
also
been
discussed.
Since
safety
paramount
aspect
any
product
get
approved,
this
delves
into
toxicological
considerations
associated
intranasal
nanosystems.
Regulatory
aspects
critical
successful
products
are
explored
review.
Overall,
underscores
significant
advancements
nanotechnology
nose-to-brain
its
potential
impact
on
management.
Abstract
Glioblastoma
(GBM)
is
a
prevalent
and
refractory
type
of
brain
tumor.
Over
the
past
two
decades,
there
have
been
minimal
advancements
in
GBM
therapy.
The
current
standard
treatment
involves
surgical
excision
followed
by
radiation
chemotherapy.
Compared
to
other
tumors,
more
challenging
treat
due
presence
glioma
stem-like
cells
(GSCs)
blood–brain
barrier,
resulting
an
extremely
low
survival
rate.
Mitochondria
play
critical
role
tumor
respiration,
metabolism,
multiple
signaling
pathways
involved
formation,
progression,
cell
apoptosis.
Consequently,
mitochondria
represent
promising
targets
for
developing
novel
anticancer
agents,
including
those
targeting
oxidative
phosphorylation,
reactive
oxygen
species
(ROS),
mitochondrial
transfer,
mitophagy.
This
review
outlines
mitochondrial-related
therapeutic
GBM,
highlighting
potential
as
target
treatment.
Glioblastoma
(GBM)
is
a
highly
malignant
brain
tumor
with
limited
treatment
options.
Polo-like
kinase
2
(PLK2),
member
of
the
polo-like
family,
has
been
variably
implicated
in
cancer,
but
its
role
GBM
not
fully
elucidated.
We
utilized
RNA-seq
data
from
multiple
databases,
including
Gene
Expression
Omnibus
(GEO),
Cancer
Genome
Atlas
(TCGA),
and
Chinese
Glioma
(CGGA),
conducted
experiments
on
human
glioma
cell
lines
to
explore
PLK2's
expression
function.
The
effects
PLK2
overexpression
viability,
proliferation,
migration,
cycle,
apoptosis
were
assessed,
tumorigenic
potential
was
evaluated
mouse
model.
consistently
downregulated
tissues
compared
normal
across
several
datasets.
Overexpression
U87MG
U251
reduced
their
enhanced
cycle
arrest
apoptosis,
significant
reductions
observed
markers.
Our
findings
suggest
that
may
potentially
function
as
suppressor
GBM.
Hence,
could
be
leveraged
therapeutic
strategy
inhibit
progression
enhance
providing
new
avenues
for
treatment.
